Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy

被引:3
作者
Colakoglu, Muhammet Kadri [1 ]
Guven, Erhan [2 ]
Akgul, Gokhan Giray [3 ]
Dogan, Lutfi [4 ]
Gulcelik, Mehmet Ali [2 ]
机构
[1] Recep Tayyip Erdogan Univ, Sch Med, Dept Surg Oncol, Rize, Turkey
[2] Univ Hlth Sci, Gulhane Res & Training Hosp, Dept Surg, Ankara, Turkey
[3] Mersin Univ, Sch Med, Dept Surg Oncol, Mersin, Turkey
[4] Univ Hlth Sci, Oncol Res & Training Hosp, Dept Surg, Ankara, Turkey
关键词
Breast cancer; methylene blue; radiocolloid; sentinel lymph node biopsy;
D O I
10.5152/ejbh.2018.3780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Breast cancer subtypes are used as prognostic and predictive factors considering the genomic profile of the disease. This study is designed to investigate the Sentinel Lymph Node (SLN) detection rate in breast cancer for different biological characteristics. Material and Methods: Patients on whom we performed the methylene blue method alone were named as Group I, radiocolloid substance method alone as Group II and both methylene blue and radiocolloid method as Group III. The results of biological tumor characteristics and characteristics of the patients on different SLN biopsy techniques were investigated. Results: The overall SLN detecting success rate was 83.3%. When considered for each group, success rate was 80% for group I, 84.9% for group II and 90.6% for group III. While a success rate of 94.6% was achieved with radiocolloid only in the patients in Luminal A and B subgroup, 90% success rate was achieved in Her2 (+) and triple negative (TN) patients with combined method. Conclusion: While successful results could be achieved by using radiocolloid substances alone in patients with Luminal A and B subtypes, combined methods should be used in HER2 (+) and TN patients.
引用
收藏
页码:100 / 104
页数:5
相关论文
共 22 条
[1]   Factors predicting failure to identify a sentinel lymph node in breast cancer [J].
Chagpar, AB ;
Martin, RC ;
Scoggins, CR ;
Carlson, DJ ;
Laidley, AL ;
El-Eid, SE ;
McGlothin, TQ ;
Noyes, RD ;
Ley, PB ;
Tuttle, TM ;
McMasters, KM .
SURGERY, 2005, 138 (01) :56-63
[2]   Factors of importance for scintigraphic non-visualisation of sentinel nodes in breast cancer [J].
Chakera, AH ;
Friis, E ;
Hesse, U ;
Al-Suliman, N ;
Zerahn, B ;
Hesse, B .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (03) :286-293
[3]   Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer [J].
Cox, CE ;
Pendas, S ;
Cox, JM ;
Joseph, E ;
Shons, AR ;
Yeatman, T ;
Ku, NN ;
Lyman, GH ;
Berman, C ;
Haddad, F ;
Reintgen, DS .
ANNALS OF SURGERY, 1998, 227 (05) :645-653
[4]  
Cox Charles E, 2002, Breast J, V8, P88, DOI 10.1046/j.1524-4741.2002.08203.x
[5]  
Dunnwald L K, 1999, J Nucl Med Technol, V27, P106
[6]   St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion [J].
Gnant, Michael ;
Thomssen, Christoph ;
Harbeck, Nadia .
BREAST CARE, 2015, 10 (02) :124-130
[7]  
Gulec SA, 1998, J NUCL MED, V39, P1388
[8]   The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review [J].
He, Pei-Sheng ;
Li, Feng ;
Li, Guan-Hua ;
Guo, Can ;
Chen, Tian-Jin .
BMC CANCER, 2016, 16
[9]   Lessons learned from 500 cases of lymphatic mapping for breast cancer [J].
Hill, ADK ;
Tran, KN ;
Akhurst, T ;
Yeung, H ;
Yeh, SDJ ;
Rosen, PP ;
Borgen, PI ;
Cody, HS .
ANNALS OF SURGERY, 1999, 229 (04) :528-535
[10]   Sentinel node detection using 99mTc-rhenium sulphide colloid in breast cancer patients:: evaluation of 1 day and 2 day protocols, and a dose-finding study [J].
Koizumi, M ;
Nomura, E ;
Yamada, Y ;
Takiguchi, T ;
Tanaka, K ;
Yoshimoto, M ;
Makita, M ;
Sakamoto, G ;
Kasumi, F ;
Ogata, E .
NUCLEAR MEDICINE COMMUNICATIONS, 2003, 24 (06) :663-670